Back to Search
Start Over
Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response
- Source :
- BMC Pulmonary Medicine, Vol 18, Iss 1, Pp 1-9 (2018)
- Publication Year :
- 2018
- Publisher :
- BMC, 2018.
-
Abstract
- Abstract Background Interleukin-5 (IL-5) antibodies represent a promising therapeutic option for patients with severe eosinophilic asthma. To date, no official treatment response criteria exist. In this study, simple criteria for treatment response applicable to all asthma patients were used to evaluate clinical efficacy and predictors for treatment response in a real-life setting. Methods Data from 42 patients with severe eosinophilic asthma treated with mepolizumab for at least six months were analysed. Simple criteria to assess treatment response in clinical practice were used: increase of FEV1 ≥ 12% or ≥ 200 ml, reduction of blood eosinophils (
Details
- Language :
- English
- ISSN :
- 14712466
- Volume :
- 18
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- BMC Pulmonary Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.970dd85401e44824ac7c5e8c7796b473
- Document Type :
- article
- Full Text :
- https://doi.org/10.1186/s12890-018-0689-2